Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Cholelithiasis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019821 Part 01, page:17 PDF 7773k",https://www.pharmapendium.com/browse/fda/Acitretin/1a0cb7a639fe6c5d73334f9d95bc1bc6?reference=17,1996.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022081/S-000 Part 01, page:65 PDF 5894k",https://www.pharmapendium.com/browse/fda/Ambrisentan/e117720ab3e6f9b3a0d7516463fe958e?reference=65,2007.0,COC([CH](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Anastrozole,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,Cholelithiasis,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020541/S-010 Part 02, page:14 PDF 2691k",https://www.pharmapendium.com/browse/fda/Anastrozole/6373bfaf67f083a9d0dc380d29635cfd?reference=14,2001.0,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Cholelithiasis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Label 021866/S-000, page:41 PDF 3491k",https://www.pharmapendium.com/browse/fda/Aripiprazole/cd74fed17ff151d875f9b8a2c02cca13?reference=41,,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Armodafinil,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1,Cholelithiasis,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021875/S-000 Part 03, page:65 PDF 7194k",https://www.pharmapendium.com/browse/fda/Armodafinil/d678f4f141624a3f2cd5f7be0fc08f3a?reference=65,2007.0,NC(=O)C[S](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
Arsenic Trioxide,O1[As]2O[As]1O2,Cholelithiasis,Human,-0.47712125471966244,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/CHMP/623089/2016; EMEA/H/C/000388/II/0058, page:49 PDF 2793k",https://www.pharmapendium.com/browse/ema/Arsenic Trioxide/fe610381fc16a4934c63adf8252ffd96?reference=49,2016.0,O1[As]2O[As]1O2
Azilsartan Kamedoxomil,CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC([O-])N1,Cholelithiasis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 200796/S-000 Part 04, page:36 PDF 6157k",https://www.pharmapendium.com/browse/fda/Azilsartan Kamedoxomil/795aa288e997610e4d3a2ddfe9669b1d?reference=36,2011.0,CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC([O-])N1
Beclomethasone Dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Cholelithiasis,Human,-3.2041199826559246,Repeated,Inhalation,"FDA approval package document: Approval Package 207921/S-000 Part 03, page:42 PDF 928k",https://www.pharmapendium.com/browse/fda/Beclomethasone Dipropionate/c56e4d1ce6b3bc7b841cc2105c9dcf37?reference=42,2016.0,[H][C]12C[CH](C)[C](OC(=O)CC)(C(=O)COC(=O)CC)[C]1(C)C[CH](O)[C]1(Cl)[C]2([H])CCC2=CC(=O)C=C[C]12C
Bempedoic Acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,Cholelithiasis,Human,-2.255272505103306,Repeated,Oral,"FDA approval package document: Approval Package 211616/S-000 Part 11, page:61 PDF 1857k",https://www.pharmapendium.com/browse/fda/Bempedoic Acid/2208c196ea39d0c896405f6c8e825e31?reference=61,2019.0,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Brexpiprazole,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,Cholelithiasis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205422/S-000 Part 04, page:81 PDF 20059k",https://www.pharmapendium.com/browse/fda/Brexpiprazole/00ccb22ace460844be09f496a697ac0d?reference=81,2014.0,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
Buprenorphine,[H][C@@]1(C[C@]23CC[C@@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Cholelithiasis,Human,-1.3010299956639813,Repeated,Skin,"FDA approval package document: Medical/Clinical Review 021306/S-000 Part 09, page:2 PDF 481k",https://www.pharmapendium.com/browse/fda/Buprenorphine/ac81c148b75e5c4579ff9b5361c2a308?reference=2,2010.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Cholelithiasis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Review 212887/S-000; 212888/S-000 Part 19, page:9 PDF 701k",https://www.pharmapendium.com/browse/fda/Cabotegravir Sodium/d8a48ae1e91b38d344fc32218cf5483b?reference=9,2019.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
"Calcitonin, Salmon",CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O,Cholelithiasis,Human,-2.3010299956639813,Repeated,Intranasal,"FDA approval package document: Approval Package 076396/S-000 Part 01, page:10 PDF 3504k","https://www.pharmapendium.com/browse/fda/Calcitonin, Salmon/54adf4b8f4223a5bfe57dca6cca09bba?reference=10",2008.0,CC(C)C[CH](NC(=O)[CH](NC(=O)[CH]1CSSC[CH](N)C(=O)N[CH](CO)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CO)C(=O)N[CH]([CH](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[CH](CCCCN)C(=O)N[CH](CC(C)C)C(=O)N[CH](CO)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC1=CN=CN1)C(=O)N[CH](CCCCN)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCC(N)=O)C(=O)N[CH]([CH](C)O)C(=O)N[CH](CC1=CC=C(O)C=C1)C(=O)N1CCC[CH]1C(=O)N[CH](CCCNC(N)=N)C(=O)N[CH]([CH](C)O)C(=O)N[CH](CC(N)=O)C(=O)N[CH]([CH](C)O)C(=O)NCC(=O)N[CH](CO)C(=O)NCC(=O)N[CH]([CH](C)O)C(=O)N1CCC[CH]1C(N)=O
Cefditoren Pivoxil,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(/C=C\C3=C(C)N=CS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)\C1=CSC(N)=N1,Cholelithiasis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021222/S-000 Part 05, page:28 PDF 1319k",https://www.pharmapendium.com/browse/fda/Cefditoren Pivoxil/c1e899a01f869658f1b031f92f357736?reference=28,2001.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(/C=C\C3=C(C)N=CS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)\C1=CSC(N)=N1
Cefpodoxime Proxetil,COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C,Cholelithiasis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050674/S-012; 050675/S-015 Part 01, page:14 PDF 1326k",https://www.pharmapendium.com/browse/fda/Cefpodoxime Proxetil/31669ae540059b1b8a6f96df9ce6c3b6?reference=14,1998.0,COCC1=C(N2[CH](SC1)[CH](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C
Ceftriaxone Sodium,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C([O-])=O)/C1=CSC(N)=N1,Cholelithiasis,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 065125/S-000, page:9 PDF 2780k",https://www.pharmapendium.com/browse/fda/Ceftriaxone Sodium/ef22a8290a78dce32100efe44fc7ec39?reference=9,2003.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C([O-])=O)/C1=CSC(N)=N1
Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,Cholelithiasis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Printed Labeling 020998/S-016, page:18 PDF 1618k",https://www.pharmapendium.com/browse/fda/Celecoxib/3576faf2cb1fb8e3a2f1aee0f7003ad9?reference=18,2003.0,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Cenobamate,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl,Cholelithiasis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 212839/S-000 Part 04, page:4 PDF 712k",https://www.pharmapendium.com/browse/fda/Cenobamate/cd26df48cc890ef82f8711c5119eea7e?reference=4,2019.0,NC(=O)O[CH](CN1N=CN=N1)C1=CC=CC=C1Cl
Cholic acid,[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@]([H])(CC[C@@]3([H])[C@]1([H])[C@H](O)C2)[C@H](C)CCC(O)=O,Cholelithiasis,Human,-2.6989700043360187,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 821k",https://www.pharmapendium.com/browse/ema/Cholic acid/27818d97aa9ede10be5951d3a7d59309?reference=6,2015.0,[H][C]12C[CH](O)CC[C]1(C)[C]1([H])C[CH](O)[C]3(C)[C]([H])(CC[C]3([H])[C]1([H])[CH](O)C2)[CH](C)CCC(O)=O
Ciprofloxacin Hydrochloride,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O,Cholelithiasis,Human,-2.6020599913279625,Repeated,Intravenous,"FDA approval package document: Approval Package 019847/S-002, S-008, S-015; 019857/S-004, S-008, S-017; 019858/S-004, S-007, S-008, S-009, S-015 Part 08, page:20 PDF 662k",https://www.pharmapendium.com/browse/fda/Ciprofloxacin Hydrochloride/472b205393340faa0a095f341f9c1ca5?reference=20,1991.0,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O
Citalopram Hydrobromide,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Cholelithiasis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 021046/S-019; 020822/S-042 Part 02, page:25 PDF 436k",https://www.pharmapendium.com/browse/fda/Citalopram Hydrobromide/3a22838868d92f333fb8ee367eaef081?reference=25,2012.0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Cholelithiasis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022561/S-000 Part 08, page:4 PDF 563k",https://www.pharmapendium.com/browse/fda/Cladribine/f27ae2cebdd652242276e7032ba19dfe?reference=4,2010.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Cholelithiasis,Human,-2.6532125137753435,Repeated,Oral,"FDA approval package document: Review 019758/S-047, page:148 PDF 10755k",https://www.pharmapendium.com/browse/fda/Clozapine/074375bc33fa11cc8237082bf942999f?reference=148,2002.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Cholelithiasis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203094/S-000 Part 05, page:76 PDF 15871k",https://www.pharmapendium.com/browse/fda/Cobicistat/cf97ec370dc39aa6baa9336ae252e4c6?reference=76,2012.0,CC(C)C1=NC(CN(C)C(=O)N[CH](CCN2CCOCC2)C(=O)N[CH](CC[CH](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
Conivaptan Hydrochloride,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,Cholelithiasis,Human,-1.9030899869919435,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 021697/S-000 Part 03, page:67 PDF 4991k",https://www.pharmapendium.com/browse/fda/Conivaptan Hydrochloride/011e8a458cc05207fd7bccbe97a4a265?reference=67,2005.0,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1
Dalfampridine,NC1=CC=NC=C1,Cholelithiasis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022250/S-000 Part 02, page:45 PDF 1108k",https://www.pharmapendium.com/browse/fda/Dalfampridine/a5ede310e62e95cb9f9abfac156e0dbf?reference=45,2009.0,NC1=CC=NC=C1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Cholelithiasis,Human,-1.3222192947339193,Repeated,Oral,"EMA approval document: ANNEX I, page:14 PDF 381k",https://www.pharmapendium.com/browse/ema/Deferasirox/1182431e287fd5965ea47ce859e9ebef?reference=14,2020.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Deferiprone,CN1C=CC(=O)C(O)=C1C,Cholelithiasis,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021825/S-000 Part 05, page:13 PDF 3049k",https://www.pharmapendium.com/browse/fda/Deferiprone/854bdd01efb0b088e3fe28b227c9037b?reference=13,2011.0,CN1C=CC(=O)C(O)=C1C
Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Cholelithiasis,Human,-2.845098040014257,Repeated,Ocular,"FDA approval package document: Approval Package 022315/S-009 Part 03, page:10 PDF 876k",https://www.pharmapendium.com/browse/fda/Dexamethasone/904a9ff956d2123eab8531f9cd86f340?reference=10,2014.0,[H][C]12C[CH](C)[C](O)(C(=O)CO)[C]1(C)C[CH](O)[C]1(F)[C]2([H])CCC2=CC(=O)C=C[C]12C
Dexlansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,Cholelithiasis,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022287/S-000 Part 01, page:31 PDF 8272k",https://www.pharmapendium.com/browse/fda/Dexlansoprazole/b4bdf5642030608f2528604c055c80d6?reference=31,2009.0,CC1=C(OCC(F)(F)F)C=CN=C1C[S](=O)C1=NC2=CC=CC=C2N1
Diclofenac Sodium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Cholelithiasis,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Review 019210, page:39 PDF 5686k",https://www.pharmapendium.com/browse/fda/Diclofenac Sodium/52d7d51ebfcf954663b975d77d5781a8?reference=39,1989.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Didanosine,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1N=CNC2=O,Cholelithiasis,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 020154/S-009, S-011, S-020; 020155/S-007, S-016; 020156/S-007, S-016 Part 10, page:1 PDF 7736k",https://www.pharmapendium.com/browse/fda/Didanosine/92b2914714832f57db669f7ea5f017e2?reference=1,1991.0,OC[CH]1CC[CH](O1)N1C=NC2=C1N=CNC2=O
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Cholelithiasis,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204790 Part 04, page:12 PDF 7848k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/1ad0a2b9727ce58261902f144c3cb335?reference=12,2012.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Donepezil Hydrochloride,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 022568/S-000, page:5 PDF 940k",https://www.pharmapendium.com/browse/fda/Donepezil Hydrochloride/30602ceb45c3031c10b630c68c395ae5?reference=5,2010.0,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Cholelithiasis,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022106/S-000 Part 03, page:10 PDF 6054k",https://www.pharmapendium.com/browse/fda/Doripenem/c864eff186d36706041572b08b92a557?reference=10,2007.0,[H][C]12[CH](C)C(S[CH]3CN[CH](CNS(N)(=O)=O)C3)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Dronedarone Hydrochloride,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,Cholelithiasis,Human,-2.9030899869919438,Repeated,Intramuscular,"EMA approval document: Assessment Report EMEA/H/C/1043/A20/005, page:13 PDF 943k",https://www.pharmapendium.com/browse/ema/Dronedarone Hydrochloride/ac8f06b056b2958a2f0f1a402458ce78?reference=13,2011.0,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12
Drospirenone,[H][C@@]12C[C@]1([H])[C@]1([H])[C@]([H])(CC[C@@]3(C)[C@@]1([H])[C@]1([H])C[C@]1([H])[C@@]31CCC(=O)O1)[C@@]1(C)CCC(=O)C=C21,Cholelithiasis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 211367 Part 05, page:29 PDF 802k",https://www.pharmapendium.com/browse/fda/Drospirenone/5e76db0121941d03580568e076e57bd3?reference=29,2019.0,[H][C]12C[C]1([H])[C]1([H])[C]([H])(CC[C]3(C)[C]1([H])[C]1([H])C[C]1([H])[C]31CCC(=O)O1)[C]1(C)CCC(=O)C=C21
Eletriptan Hydrobromide,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,Cholelithiasis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021016/S-000 Part 04, page:42 PDF 1803k",https://www.pharmapendium.com/browse/fda/Eletriptan Hydrobromide/a93ca5efe23502ee7d9857dc8627193d?reference=42,2002.0,CN1CCC[CH]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Cholelithiasis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 204629/S-005 Part 06, page:45 PDF 9197k",https://www.pharmapendium.com/browse/fda/Empagliflozin/6569af33b43cef5b3ac837350828772d?reference=45,2016.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Ertapenem Sodium,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C([O-])=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Cholelithiasis,Human,-3.0,Repeated,Parenteral,"FDA approval package document: Approval Package 021337/S-021 Part 01, page:20 PDF 464k",https://www.pharmapendium.com/browse/fda/Ertapenem Sodium/c6cafc1e218c427b66cfdc7cc64a1691?reference=20,2006.0,[H][C]12[CH](C)C(S[CH]3CN[CH](C3)C(=O)NC3=CC(=CC=C3)C([O-])=O)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Estradiol,[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CCC1=C2C=CC(O)=C1,Cholelithiasis,Human,-1.0,Repeated,Intravaginal,"FDA approval package document: Approval Package 020908/S-013 Part 10, page:3 PDF 1337k",https://www.pharmapendium.com/browse/fda/Estradiol/8e37643b2860a265a5568d67e17c28ca?reference=3,2008.0,[H][C]12CC[C]3(C)[CH](O)CC[C]3([H])[C]1([H])CCC1=C2C=CC(O)=C1
Estradiol Acetate,[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CCC1=C2C=CC(OC(C)=O)=C1,Cholelithiasis,Human,-1.6989700043360187,Repeated,Intravaginal,"FDA approval package document: Medical/Clinical Review 021367/S-000, page:44 PDF 2067k",https://www.pharmapendium.com/browse/fda/Estradiol Acetate/99a38835de4458e279945b05b577c403?reference=44,2001.0,[H][C]12CC[C]3(C)[CH](O)CC[C]3([H])[C]1([H])CCC1=C2C=CC(OC(C)=O)=C1
Eszopiclone,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=C1N=CC=N2)C1=NC=C(Cl)C=C1,Cholelithiasis,Human,-0.3010299956639812,Repeated,Oral,Reference from PharmaPendium Published Toxicity: eszopiclone_cia-2-313   ---   JOURNAL:Clinical Interventions in Aging   PAGES:313   VOLUME:2,,2007.0,CN1CCN(CC1)C(=O)O[CH]1N(C(=O)C2=C1N=CC=N2)C1=NC=C(Cl)C=C1
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Cholelithiasis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 020584 Part 01, page:79 PDF 6920k",https://www.pharmapendium.com/browse/fda/Etodolac/e22b8461e3fed34ddd98a7583998f91d?reference=79,1996.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Etonogestrel,[H][C@]12CCC(=O)C=C1CC[C@@]1([H])[C@]3([H])CC[C@@](O)(C#C)[C@@]3(CC)CC(=C)[C@]21[H],Cholelithiasis,Human,-1.8325089127062364,Repeated,Implant,"FDA approval package document: Medical/Clinical Review 021529/S-000 Part 03, page:1 PDF 4708k",https://www.pharmapendium.com/browse/fda/Etonogestrel/acb047696f210487981a421de99ad085?reference=1,2006.0,[H][C]12CCC(=O)C=C1CC[C]1([H])[C]3([H])CC[C](O)(C#C)[C]3(CC)CC(=C)[C]21[H]
Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 021445/S-013, page:14 PDF 429k",https://www.pharmapendium.com/browse/fda/Ezetimibe/14e08036769a34cbfa47a8d80e04d720?reference=14,2006.0,O[CH](CC[CH]1[CH](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Ezogabine,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,Cholelithiasis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022345/S-000 Part 09, page:13 PDF 798k",https://www.pharmapendium.com/browse/fda/Ezogabine/32ffc5ac0f220009d9a5886e136f3359?reference=13,2011.0,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
Famciclovir,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O,Cholelithiasis,Human,-3.0,Repeated,Oral,"FDA approval package document: Medical Officer Review 020363, page:36 PDF 1407k",https://www.pharmapendium.com/browse/fda/Famciclovir/d4874c5cf052c8ae39ef4000f7aec5ca?reference=36,1996.0,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Cholelithiasis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:8 PDF 554k",https://www.pharmapendium.com/browse/ema/Febuxostat/90530b38818991c7a21225414abfe220?reference=8,2020.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,Cholelithiasis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019834/S-001, S-002, S-009 Part 08, page:37 PDF 6712k",https://www.pharmapendium.com/browse/fda/Felodipine/b6a4c7f7a92ebdea56e46db941d2f4b6?reference=37,1997.0,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,Cholelithiasis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019304 Part 03, page:54 PDF 7698k",https://www.pharmapendium.com/browse/fda/Fenofibrate/7c467e5c47086a300ef271deadab1c7d?reference=54,1993.0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Fenofibric Acid,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O,Cholelithiasis,Human,-2.0211892990699383,Repeated,Oral,"FDA approval package document: Label 022418/S-000, page:2 PDF 1181k",https://www.pharmapendium.com/browse/fda/Fenofibric Acid/2f262e6a8aa1c940b43c4ff43251fd55?reference=2,2009.0,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Cholelithiasis,Human,-2.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 06, page:5 PDF 321k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/2e7486baa94f570d20d465293556c8a8?reference=5,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,Cholelithiasis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022526/S-000 Part 05, page:7 PDF 791k",https://www.pharmapendium.com/browse/fda/Flibanserin/0b41d75c09308b12e0dc7995fdfd2b7d?reference=7,2010.0,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Cholelithiasis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 018936/S-026 Part 41, page:13 PDF 3833k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/119e730a3786e7370bb0c9862b3214a2?reference=13,1987.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Fluticasone Furoate,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Cholelithiasis,Human,-2.0,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 205625/S-000, page:80 PDF 11952k",https://www.pharmapendium.com/browse/fda/Fluticasone Furoate/82dd81c768a0870f1b9ba46341c7a734?reference=80,2013.0,[H][C]12C[CH](C)[C](OC(=O)C3=CC=CO3)(C(=O)SCF)[C]1(C)C[CH](O)[C]1(F)[C]2([H])C[CH](F)C2=CC(=O)C=C[C]12C
Fluticasone Propionate,[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Cholelithiasis,Human,-3.0,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 208798/S-000, page:136 PDF 18534k",https://www.pharmapendium.com/browse/fda/Fluticasone Propionate/e0d19891639bb6dbe0eb33be98b0b680?reference=136,2016.0,[H][C]12C[CH](C)[C](OC(=O)CC)(C(=O)SCF)[C]1(C)C[CH](O)[C]1(F)[C]2([H])C[CH](F)C2=CC(=O)C=C[C]12C
Fluvastatin Sodium,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,Cholelithiasis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020261 Part 13, page:8 PDF 7437k",https://www.pharmapendium.com/browse/fda/Fluvastatin Sodium/f20fb59e2770165d18a2885af438f004?reference=8,1993.0,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[CH](O)C[CH](O)CC([O-])=O
Fostamatinib disodium,COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)N(COP([O-])([O-])=O)C4=N3)=N2)=CC(OC)=C1OC,Cholelithiasis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/654949/2019; EMEA/H/C/005012/0000, page:143 PDF 12246k",https://www.pharmapendium.com/browse/ema/Fostamatinib disodium/8c9910372f26ae5915aefd4ef4c6f0d7?reference=143,2019.0,COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)N(COP([O-])([O-])=O)C4=N3)=N2)=CC(OC)=C1OC
Gabapentin Enacarbil,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(O)=O,Cholelithiasis,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022399/S-000 Part 03, page:28 PDF 6981k",https://www.pharmapendium.com/browse/fda/Gabapentin Enacarbil/e88b89812bbb2c53c47b7c13771f688c?reference=28,2010.0,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(O)=O
Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,Cholelithiasis,Human,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Label 209347/S-000, page:11 PDF 604k",https://www.pharmapendium.com/browse/fda/Ganciclovir/d7c8931bcde90adb29b20b261a09c38d?reference=11,2017.0,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Ganciclovir Sodium,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1,Cholelithiasis,Human,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Label 019661/S-030, page:20 PDF 690k",https://www.pharmapendium.com/browse/fda/Ganciclovir Sodium/0078e0911648eae74c95fa905199c725?reference=20,2006.0,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1
Ibandronate Sodium,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O,Cholelithiasis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021455/S-000 Part 03, page:10 PDF 1354k",https://www.pharmapendium.com/browse/fda/Ibandronate Sodium/2c902652a50878277ffa8d5adb5f08db?reference=10,2003.0,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O
Iloperidone,COC1=CC(=CC=C1OCCCN1CCC(CC1)C1=NOC2=CC(F)=CC=C12)C(C)=O,Cholelithiasis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Summary Review 022192/S-000, page:14 PDF 3558k",https://www.pharmapendium.com/browse/fda/Iloperidone/88192b593916eb7221a4a9d4e8fa6c38?reference=14,,COC1=CC(=CC=C1OCCCN1CCC(CC1)C1=NOC2=CC(F)=CC=C12)C(C)=O
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Cholelithiasis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022484/S-000 Part 01, page:11 PDF 999k",https://www.pharmapendium.com/browse/fda/Itraconazole/892e96991ab436c9771803aece2a8c31?reference=11,2010.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Cholelithiasis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022253/S-000; 022254/S-000 Part 03, page:92 PDF 6885k",https://www.pharmapendium.com/browse/fda/Lacosamide/e8591abb7cc398480feaf4f98f1b54e2?reference=92,2008.0,COC[CH](NC(C)=O)C(=O)NCC1=CC=CC=C1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl,Cholelithiasis,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022509/S-000 Part 03, page:4 PDF 405k",https://www.pharmapendium.com/browse/fda/Lamotrigine/7a906752dd615052ec50add93b5ada30?reference=4,2009.0,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Cholelithiasis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020406/S-006, page:20 PDF 1333k",https://www.pharmapendium.com/browse/fda/Lansoprazole/19f710bfb32c5eeb9a96173f5781f6ce?reference=20,1996.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Lasofoxifene,OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1,Cholelithiasis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 474k",https://www.pharmapendium.com/browse/ema/Lasofoxifene/4a30d26487d86d298e55209f18660544?reference=7,2013.0,OC1=CC=C2[CH]([CH](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Cholelithiasis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020905/S-000 Part 02, page:4 PDF 1494k",https://www.pharmapendium.com/browse/fda/Leflunomide/561bf44b5b0cb12e901266599c64bbe8?reference=4,1998.0,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Lesinurad,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1,Cholelithiasis,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/6459/2016; EMEA/H/C/003932/0000, page:110 PDF 5667k",https://www.pharmapendium.com/browse/ema/Lesinurad/d22d8c9f5d65c0aae620ada4cabc6eaa?reference=110,2015.0,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1
Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,Cholelithiasis,Human,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021035, page:60 PDF 3117k",https://www.pharmapendium.com/browse/fda/Levetiracetam/03d6b5e8161990580f1e2daa4505b7b4?reference=60,1999.0,CC[CH](N1CCCC1=O)C(N)=O
Levodopa,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,Cholelithiasis,Human,-0.6989700043360189,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 209184/S-000 Part 05, page:11 PDF 636k",https://www.pharmapendium.com/browse/fda/Levodopa/9a62595a6b475d47c1f31f6e75885faf?reference=11,2018.0,N[CH](CC1=CC(O)=C(O)C=C1)C(O)=O
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Cholelithiasis,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 020634/S-028; 020635/S-027 Part 01, page:32 PDF 6823k",https://www.pharmapendium.com/browse/fda/Levofloxacin/fde9c2ebdefc64354e914d50d204a952?reference=32,2003.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Levomilnacipran Hydrochloride,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1,Cholelithiasis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204168/S-000 Part 04, page:34 PDF 8673k",https://www.pharmapendium.com/browse/fda/Levomilnacipran Hydrochloride/0503671a14b537e80790826db3f43ca2?reference=34,2012.0,CCN(CC)C(=O)[C]1(C[CH]1CN)C1=CC=CC=C1
Levonorgestrel,[H][C@]12CCC(=O)C=C1CC[C@]1([H])[C@]2([H])CC[C@@]2(CC)[C@@]1([H])CC[C@@]2(O)C#C,Cholelithiasis,Human,-0.7781512503836436,Repeated,Intrauterine,"FDA approval package document: Medical/Clinical Review 206229/S-000, page:70 PDF 16181k",https://www.pharmapendium.com/browse/fda/Levonorgestrel/7e535a6d9e1c2e0ee1edccb8ceca1b01?reference=70,2015.0,[H][C]12CCC(=O)C=C1CC[C]1([H])[C]2([H])CC[C]2(CC)[C]1([H])CC[C]2(O)C#C
Linaclotide,[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC(=O)[C@]4([H])CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@]([H])(CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,Cholelithiasis,Human,-2.462397997898956,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202811/S-000 Part 12, page:46 PDF 760k",https://www.pharmapendium.com/browse/fda/Linaclotide/96c54241c9164f8aac1979b070477fae?reference=46,2012.0,[H][C]1(CSSC[C]2([H])NC(=O)[CH](CC3=CC=C(O)C=C3)NC(=O)[CH](CCC(O)=O)NC(=O)[C]3([H])CSSC[C]([H])(NC(=O)[CH](C)NC(=O)[C]4([H])CCCN4C(=O)[CH](CC(N)=O)NC(=O)[C]([H])(CSSC[CH](N)C(=O)N3)NC2=O)C(=O)N[C]([H])([CH](C)O)C(=O)NCC(=O)N1)C(=O)N[CH](CC1=CC=C(O)C=C1)C(O)=O
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Cholelithiasis,Human,-0.9030899869919435,Repeated,Subcutaneous,"FDA approval package document: Approval Package 022341/S-027 Part 13, page:13 PDF 1332k",https://www.pharmapendium.com/browse/fda/Liraglutide/79ec343baeab356f6ffa1db4fb5d3171?reference=13,2016.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lorcaserin Hydrochloride,C[C@H]1CNCCC2=CC=C(Cl)C=C12,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022529/S-000 Part 09, page:66 PDF 2134k",https://www.pharmapendium.com/browse/fda/Lorcaserin Hydrochloride/290b233d73c8c3628efb1f5e7797d526?reference=66,2012.0,C[CH]1CNCCC2=CC=C(Cl)C=C12
Losartan Potassium,CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Cholelithiasis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020386/S-032 Part 02, page:47 PDF 1981k",https://www.pharmapendium.com/browse/fda/Losartan Potassium/438edb75f70f0b616380d7fde1ebcfa7?reference=47,2003.0,CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Lurasidone Hydrochloride,[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O,Cholelithiasis,Human,-2.2041199826559246,Repeated,Oral,"EMA approval document: Assessment Report EMA/113836/2014; EMEA/H/C/002713/0000, page:134 PDF 2824k",https://www.pharmapendium.com/browse/ema/Lurasidone Hydrochloride/194c2612915ca09c6100d9ae9bfa6934?reference=134,2014.0,[H][C]12[CH]3CC[CH](C3)[C]1([H])C(=O)N(C[CH]1CCCC[CH]1CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O
Memantine Hydrochloride,[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,Cholelithiasis,Human,-1.4471580313422192,Repeated,Oral,"FDA approval package document: Label 022525/S-000, page:8 PDF 368k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/456f9296816fa8a789fea898abe00faa?reference=8,2010.0,[H][C]12C[C]3(C)C[C](C)(C1)C[C](N)(C2)C3
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Cholelithiasis,Human,-1.6989700043360187,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021506/S-000, page:86 PDF 10222k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/6efecc784fac818938515cd0c9f1d90a?reference=86,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Moexipril Hydrochloride,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O,Cholelithiasis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical Officer Review 020312, page:45 PDF 3555k",https://www.pharmapendium.com/browse/fda/Moexipril Hydrochloride/2995111eb14a4a6ee2ea9721fa35501e?reference=45,1993.0,CCOC(=O)[CH](CCC1=CC=CC=C1)N[CH](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[CH]1C(O)=O
Monoctanoin,CCCCCCCC(=O)OCC(O)CO,Cholelithiasis,Human,-1.0,Repeated,Parenteral,"FDA approval package document: Approval Package 019368/S-001, S-002 Part 01, page:37 PDF 3790k",https://www.pharmapendium.com/browse/fda/Monoctanoin/103031764c0e06310a7f9d7011ab1653?reference=37,1985.0,CCCCCCCC(=O)OCC(O)CO
Nabumetone,COC1=CC2=CC=C(CCC(C)=O)C=C2C=C1,Cholelithiasis,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019583/S-011 Part 03, page:9 PDF 1310k",https://www.pharmapendium.com/browse/fda/Nabumetone/e69c5ebfb2455d65a28fedfe8563e5cf?reference=9,1995.0,COC1=CC2=CC=C(CCC(C)=O)C=C2C=C1
Naproxen Sodium,COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C([O-])=O,Cholelithiasis,Human,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 020353 Part 01, page:45 PDF 659k",https://www.pharmapendium.com/browse/fda/Naproxen Sodium/92cbed8636118d690713ebb53d4409fc?reference=45,1996.0,COC1=CC2=CC=C(C=C2C=C1)[CH](C)C([O-])=O
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Cholelithiasis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201152/S-000 Part 05, page:10 PDF 347k",https://www.pharmapendium.com/browse/fda/Nevirapine/6da9b8e6076254afeebf80bca57bb955?reference=10,2011.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Cholelithiasis,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/313746/2017; EMEA/H/C/000798/II/0084/G, page:63 PDF 2138k",https://www.pharmapendium.com/browse/ema/Nilotinib Hydrochloride Monohydrate/d01e77935612f8a2f5c9961a577b6a3b?reference=63,2017.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Nilutamide,CC1(C)NC(=O)N(C2=CC=C(C(=C2)C(F)(F)F)N(=O)=O)C1=O,Cholelithiasis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical Officer Review 020169, page:14 PDF 591k",https://www.pharmapendium.com/browse/fda/Nilutamide/fc6a923cc670cfaa1045fa4ebf0f27f4?reference=14,1995.0,CC1(C)NC(=O)N(C2=CC=C(C(=C2)C(F)(F)F)N(=O)=O)C1=O
Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Cholelithiasis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207999/S-000 Part 04, page:76 PDF 18785k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/fd9575acfa8e5dadbfa0aa39e5adfd26?reference=76,2016.0,[H][C]1(CC[C]2([H])[C]3([H])[CH](O)[CH](CC)[C]4([H])C[CH](O)CC[C]4(C)[C]3([H])CC[C]12C)[CH](C)CCC(O)=O
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 020592/S-018, page:47 PDF 9673k",https://www.pharmapendium.com/browse/fda/Olanzapine/9a4016466bda48209e57278f6d017b9e?reference=47,2003.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Cholelithiasis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019810/S-002, S-007, S-036, S-037, S-009, S-010, S-022, S-035, S-019, S-023, S-025, S-033, S-034; 050662/S-010 Part 21, page:19 PDF 6127k",https://www.pharmapendium.com/browse/fda/Omeprazole/1f18354d13e32eec8cbbb691e34fed35?reference=19,1990.0,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Cholelithiasis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 020766/S-000 Part 02, page:5 PDF 700k",https://www.pharmapendium.com/browse/fda/Orlistat/176b5b10a4c7e915140b2ae6a6e36b67?reference=5,1999.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12,Cholelithiasis,Human,-3.380211241711606,Repeated,Oral,"FDA approval package document: Approval Package 078734/S-000 Part 02, page:6 PDF 4827k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/e640954ff6d039d46590299b60b86f2c?reference=6,2009.0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12
Paliperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C(=O)N2CCCC(O)C2=N1,Cholelithiasis,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021999/S-000 Part 07, page:37 PDF 6211k",https://www.pharmapendium.com/browse/fda/Paliperidone/3fbc991429938a0b5ac13b2057d00708?reference=37,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C(=O)N2CCCC(O)C2=N1
Paliperidone Palmitate,CCCCCCCCCCCCCCCC(=O)O[C@@H]1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=CC(F)=CC=C34)=C(C)N=C12,Cholelithiasis,Human,-1.8750612633917,Repeated,Intramuscular,"EMA approval document: ANNEX I, page:32 PDF 528k",https://www.pharmapendium.com/browse/ema/Paliperidone Palmitate/4945c9953b218d971366d3a467544b2c?reference=32,2020.0,CCCCCCCCCCCCCCCC(=O)O[CH]1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=CC(F)=CC=C34)=C(C)N=C12
Paroxetine Hydrochloride,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,Cholelithiasis,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 077873/S-000 Part 03, page:1 PDF 412k",https://www.pharmapendium.com/browse/fda/Paroxetine Hydrochloride/a509e558c60afc1d47a8429b40106097?reference=1,2007.0,FC1=CC=C(C=C1)[CH]1CCNC[CH]1COC1=CC=C2OCOC2=C1
Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Cholelithiasis,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Scientific Discussion, page:20 PDF 297k",https://www.pharmapendium.com/browse/ema/Pioglitazone Hydrochloride/7e2fe86f1eb5292bd0df81d1b7d3a5de?reference=20,2003.0,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Cholelithiasis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022003/S-000, page:125 PDF 8671k",https://www.pharmapendium.com/browse/fda/Posaconazole/f5037214d79cab10872dcc1e689683b6?reference=125,2005.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pramipexole Dihydrochloride,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Cholelithiasis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 022514/S-000, page:7 PDF 459k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/670aee328b4355c20f586428ea2fcc64?reference=7,2010.0,CCCN[CH]1CCC2=C(C1)SC(N)=N2
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Cholelithiasis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Label 021446/S-028, page:21 PDF 729k",https://www.pharmapendium.com/browse/fda/Pregabalin/11c0e2c99a01b154dbedae07c3f1622a?reference=21,2012.0,CC(C)C[CH](CN)CC(O)=O
Progesterone,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O,Cholelithiasis,Human,-2.0,Repeated,Intravaginal,"FDA approval package document: Medical/Clinical Review 022057/S-000 Part 01, page:14 PDF 6452k",https://www.pharmapendium.com/browse/fda/Progesterone/55c1fff1ab48056a24f2d79e1d0a77d1?reference=14,2006.0,[H][C]1(CC[C]2([H])[C]3([H])CCC4=CC(=O)CC[C]4(C)[C]3([H])CC[C]12C)C(C)=O
Propafenone Hydrochloride,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,Cholelithiasis,Human,-2.5118833609788744,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021416/S-000 Part 03, page:31 PDF 1504k",https://www.pharmapendium.com/browse/fda/Propafenone Hydrochloride/b5a929c4f356880d103269550916a1d9?reference=31,2002.0,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Cholelithiasis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020973, page:76 PDF 3861k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/cd5324d145f95f7fb7f9add29725eb72?reference=76,1999.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raloxifene Hydrochloride,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,Cholelithiasis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022042/S-000 Part 03, page:32 PDF 5461k",https://www.pharmapendium.com/browse/fda/Raloxifene Hydrochloride/58eb58a95868dc2b7fb7f30e50e38887?reference=32,2007.0,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
Ranitidine Hydrochloride,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,Cholelithiasis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019675/S-012, S-013, S-016; 018703/S-046, S-050, S-019, S-042, S-047 Part 08, page:55 PDF 9533k",https://www.pharmapendium.com/browse/fda/Ranitidine Hydrochloride/611752294370761886d2e59319974880?reference=55,1994.0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Cholelithiasis,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Review 203085/S-000 Part 05, page:5 PDF 548k",https://www.pharmapendium.com/browse/fda/Regorafenib/0067e7a1c5e1d5ee463074c04d918f5b?reference=5,2012.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Cholelithiasis,Human,-3.146128035678238,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/298637/2012; EMEA/H/C/000246/WS/0216, page:62 PDF 1670k",https://www.pharmapendium.com/browse/ema/Ribavirin/24f457141833d61a616a896608af587a?reference=62,2012.0,NC(=O)C1=NN(C=N1)[CH]1O[CH](CO)[CH](O)[CH]1O
Rilpivirine Hydrochloride,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Cholelithiasis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202022/S-000, page:52 PDF 1064k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/9ced65a4af087352a74203f63a45eb54?reference=52,2011.0,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
Rimonabant,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1,Cholelithiasis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Scientific Discussion EMEA/H/C/666/II/04, page:7 PDF 354k",https://www.pharmapendium.com/browse/ema/Rimonabant/70171e4e539045ae5e7a485abb0f9b5d?reference=7,2007.0,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
Risedronate Sodium,OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)([O-])=O,Cholelithiasis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020835, page:12 PDF 3171k",https://www.pharmapendium.com/browse/fda/Risedronate Sodium/4b91218ae65dbb3fdd344de6b389c5f0?reference=12,1999.0,OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)([O-])=O
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Cholelithiasis,Human,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Approval Package 020272/S-036 Part 02, page:36 PDF 407k",https://www.pharmapendium.com/browse/fda/Risperidone/2a95bb63c1c011ce22ff69a665b3e802?reference=36,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Cholelithiasis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/42547/2012; EMEA/H/C/000944/II/0012, page:35 PDF 1855k",https://www.pharmapendium.com/browse/ema/Rivaroxaban/3586f5168b6474e33234023794a720d3?reference=35,2011.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Ropinirole Hydrochloride,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2,Cholelithiasis,Human,-1.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022008/S-000 Part 02, page:60 PDF 6061k",https://www.pharmapendium.com/browse/fda/Ropinirole Hydrochloride/7877e264d766ba51735bdd6381a5f4f7?reference=60,2008.0,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Cholelithiasis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 021366/S-010 Part 02, page:39 PDF 7895k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/7e44b12dc2d51e53badbf45757689a3b?reference=39,2007.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Saxagliptin Hydrochloride,[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)[C@H](N)C(=O)N1[C@@H](C[C@]2([H])C[C@]12[H])C#N,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022350/S-000 Part 02, page:29 PDF 7700k",https://www.pharmapendium.com/browse/fda/Saxagliptin Hydrochloride/f655ce6372bb37a28b774eb72e961cf9?reference=29,2009.0,[H][C]12C[C]3([H])C[C](O)(C1)C[C](C2)(C3)[CH](N)C(=O)N1[CH](C[C]2([H])C[C]12[H])C#N
Selegiline Hydrochloride,C[C@H](CC1=CC=CC=C1)N(C)CC#C,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021479/S-000 Part 05, page:58 PDF 7135k",https://www.pharmapendium.com/browse/fda/Selegiline Hydrochloride/56e6ec919655048aad42bacb617c497f?reference=58,2005.0,C[CH](CC1=CC=CC=C1)N(C)CC#C
Sibutramine Hydrochloride,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1,Cholelithiasis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Label 020632/S-026, page:25 PDF 449k",https://www.pharmapendium.com/browse/fda/Sibutramine Hydrochloride/b4146d51261d5cb8abba7bdc27f31629?reference=25,2006.0,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
Simeprevir Sodium,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,Cholelithiasis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205123/S-000 Part 11, page:10 PDF 2371k",https://www.pharmapendium.com/browse/fda/Simeprevir Sodium/edcc84fc86e3aa2b7352c0d0b89a028d?reference=10,2013.0,[H][C]12C[C]1(NC(=O)[C]1([H])C[CH](C[C]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1
Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,Cholelithiasis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019766/S-001, S-002, S-003, S-004, S-005, S-006; 019643/S-041, S-007, S-009, S-037, S-010, S-011, S-013, S-021, S-015 Part 02, page:64 PDF 11296k",https://www.pharmapendium.com/browse/fda/Simvastatin/f141ffb9aa064e4bfa6d49f39657cefe?reference=64,1991.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)C(C)(C)CC
Sodium Oxybate,OCCCC([O-])=O,Cholelithiasis,Human,-3.9542425094393248,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021196/S-000 Part 10, page:2 PDF 1551k",https://www.pharmapendium.com/browse/fda/Sodium Oxybate/8284148121cddd830616b0e2c1af886e?reference=2,2001.0,OCCCC([O-])=O
Strontium Ranelate,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,Cholelithiasis,Human,-3.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/353622/2012, page:47 PDF 2244k",https://www.pharmapendium.com/browse/ema/Strontium Ranelate/917003a5e07638146377f1055ef01a72?reference=47,2012.0,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Cholelithiasis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 01, page:15 PDF 10320k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/bccf76edc873f241b1898b3994cb3b19?reference=15,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tadalafil,[H][C@]12CC3=C(NC4=C3C=CC=C4)[C@H](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1,Cholelithiasis,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022332/S-000, page:43 PDF 5294k",https://www.pharmapendium.com/browse/fda/Tadalafil/38253453d730cfa85a5df5d153089ac2?reference=43,2009.0,[H][C]12CC3=C(NC4=C3C=CC=C4)[CH](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1
Terazosin Hydrochloride,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1CCCO1,Cholelithiasis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020223/S-006 Part 06, page:44 PDF 6049k",https://www.pharmapendium.com/browse/fda/Terazosin Hydrochloride/3478da3f3e64fa54ba3710c6d07f9a9f?reference=44,1993.0,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1CCCO1
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Cholelithiasis,Human,-0.8450980400142568,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:58 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=58,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Ticagrelor,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1,Cholelithiasis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 022433/S-015 Part 09, page:7 PDF 1421k",https://www.pharmapendium.com/browse/fda/Ticagrelor/5a721b6d8938049d53c2c05412bf3c4d?reference=7,2015.0,CCCSC1=NC(N[CH]2C[CH]2C2=CC=C(F)C(F)=C2)=C2N=NN([CH]3C[CH](OCCO)[CH](O)[CH]3O)C2=N1
Tiotropium Bromide,[H][C@]12O[C@@]1([H])[C@]1([H])C[C@H](C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,Cholelithiasis,Human,-1.0,Repeated,Inhalation,"FDA approval package document: Summary Review 207070/S-000, page:22 PDF 3331k",https://www.pharmapendium.com/browse/fda/Tiotropium Bromide/e11ce940547141e88351455a9b4af247?reference=22,2015.0,[H][C]12O[C]1([H])[C]1([H])C[CH](C[C]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Tolcapone,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O,Cholelithiasis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020697 Part 02, page:11 PDF 623k",https://www.pharmapendium.com/browse/fda/Tolcapone/f87eab26dba71df35c944559f3c78b15?reference=11,1996.0,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O
Topiramate,[H][C@@]12OC(C)(C)O[C@]1(COS(N)(=O)=O)OC[C@H]1OC(C)(C)O[C@@H]21,Cholelithiasis,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020505/S-001 Part 04, page:23 PDF 1246k",https://www.pharmapendium.com/browse/fda/Topiramate/9dd45424ad0d97ccb83413dc150cb4e4?reference=23,1999.0,[H][C]12OC(C)(C)O[C]1(COS(N)(=O)=O)OC[CH]1OC(C)(C)O[CH]21
Tramadol Hydrochloride,COC1=CC(=CC=C1)[C@]1(O)CCCC[C@H]1CN(C)C,Cholelithiasis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022370/S-000 Part 10, page:7 PDF 315k",https://www.pharmapendium.com/browse/fda/Tramadol Hydrochloride/73fe0739ed0a22226115e76e9f405f0e?reference=7,2008.0,COC1=CC(=CC=C1)[C]1(O)CCCC[CH]1CN(C)C
Trandolapril,[H][C@]12CCCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Cholelithiasis,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 020528/S-001 Part 04, page:84 PDF 8710k",https://www.pharmapendium.com/browse/fda/Trandolapril/28cf030625dfb443a2aa514c42664d82?reference=84,1996.0,[H][C]12CCCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Ubrogepant,C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CC3=C(C[C@]4(C3)C(=O)NC3=C4C=CC=N3)N=C2)C(=O)N1CC(F)(F)F)C1=CC=CC=C1,Cholelithiasis,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 211765/S-000 Part 03, page:5 PDF 2440k",https://www.pharmapendium.com/browse/fda/Ubrogepant/7cab66b396a8d5b03d801c01ae1e0fc0?reference=5,2019.0,C[CH]1[CH](C[CH](NC(=O)C2=CC3=C(C[C]4(C3)C(=O)NC3=C4C=CC=N3)N=C2)C(=O)N1CC(F)(F)F)C1=CC=CC=C1
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Cholelithiasis,Human,-1.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/84021/2015; EMEA/H/C/002041/II/0028, page:46 PDF 4975k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/88e54d22b1add642a5687c34a8150a02?reference=46,2015.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Upadacitinib,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F,Cholelithiasis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 211675/S-000 Part 03, page:25 PDF 926k",https://www.pharmapendium.com/browse/fda/Upadacitinib/549d1ac1d20d143d93ad6a7972207387?reference=25,2019.0,CC[CH]1CN(C[CH]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
Valdecoxib,CC1=C(C2=CC=C(C=C2)S(N)(=O)=O)C(=NO1)C1=CC=CC=C1,Cholelithiasis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021341/S-000 Part 03, page:86 PDF 3669k",https://www.pharmapendium.com/browse/fda/Valdecoxib/393cae7dcde505c5b787ef005d70b3c6?reference=86,2001.0,CC1=C(C2=CC=C(C=C2)S(N)(=O)=O)C(=NO1)C1=CC=CC=C1
Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)[C@@H](C(C)C)C(O)=O,Cholelithiasis,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Approval Package 021283/S-024 Part 04, page:34 PDF 6942k",https://www.pharmapendium.com/browse/fda/Valsartan/a94b0a05be91292791b1c64b7e5b9754?reference=34,2007.0,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)[CH](C(C)C)C(O)=O
Vandetanib,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,Cholelithiasis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:38 PDF 353k",https://www.pharmapendium.com/browse/ema/Vandetanib/845e7aa9cb34604f36532442b44c75f6?reference=38,2020.0,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1
Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,Cholelithiasis,Human,-2.9822712330395684,Repeated,Oral,"EMA approval document: Assessment Report EMA/200986/2012; EMEA/H/C/002409, page:77 PDF 1852k",https://www.pharmapendium.com/browse/ema/Vemurafenib/3f4e6b934f558fc729afc31971243828?reference=77,2011.0,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Venetoclax,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC=C(NCC3CCOCC3)C(=C2)N(=O)=O)=C(C1)C1=CC=C(Cl)C=C1,Cholelithiasis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 208573/S-020; 208573/S-021 Part 12, page:42 PDF 799k",https://www.pharmapendium.com/browse/fda/Venetoclax/bfe5b79a9757278e22acc64de6f11eaf?reference=42,2020.0,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC=C(NCC3CCOCC3)C(=C2)N(=O)=O)=C(C1)C1=CC=C(Cl)C=C1
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Cholelithiasis,Human,-2.3521825181113627,Repeated,Oral,"FDA approval package document: Label 022104/S-000, page:19 PDF 3066k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/e87ef146efbee14f7cabdd861bd01b9e?reference=19,,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Vigabatrin,NC(CCC(O)=O)C=C,Cholelithiasis,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 02, page:15 PDF 6981k",https://www.pharmapendium.com/browse/fda/Vigabatrin/8df119ca2ebfd8c7300d5bc513a92a8d?reference=15,2009.0,NC(CCC(O)=O)C=C
Vildagliptin,[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)NCC(=O)N1CCC[C@@H]1C#N,Cholelithiasis,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/568007/2012; EMEA/H/C/xxxx/WS/0272, page:26 PDF 927k",https://www.pharmapendium.com/browse/ema/Vildagliptin/fe408fa09825aded38db507205053ac7?reference=26,2012.0,[H][C]12C[C]3([H])C[C](O)(C1)C[C](C2)(C3)NCC(=O)N1CCC[CH]1C#N
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Cholelithiasis,Human,-1.0791812460476249,Repeated,Intravenous,"FDA approval package document: Approval Package 021266/S-009, 021267/S-009, 021630/S-003 Part 03, page:15 PDF 309k",https://www.pharmapendium.com/browse/fda/Voriconazole/6bf2dd491c6903c4f6aa215436a65f75?reference=15,2004.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Vortioxetine Hydrobromide,CC1=CC(C)=C(SC2=CC=CC=C2N2CCNCC2)C=C1,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204447/S-000 Part 03, page:72 PDF 2976k",https://www.pharmapendium.com/browse/fda/Vortioxetine Hydrobromide/aea7100e8e140087e83ec01cf36faab7?reference=72,2012.0,CC1=CC(C)=C(SC2=CC=CC=C2N2CCNCC2)C=C1
Zaleplon,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,Cholelithiasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020859/S-000 Part 06, page:12 PDF 873k",https://www.pharmapendium.com/browse/fda/Zaleplon/6075255fd9a5706c10b94a32ec3d6f08?reference=12,,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N
Zomepirac,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1,Cholelithiasis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018236/S-008, S-009, S-015, S-017, S-018, S-024 Part 02, page:34 PDF 5050k",https://www.pharmapendium.com/browse/fda/Zomepirac/0b348a66d2f74804d192bcee4ba5cf23?reference=34,1983.0,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,Cholelithiasis,Human,-2.6989700043360187,Repeated,Oral,"EMA approval document: ANNEX I, page:41 PDF 567k",https://www.pharmapendium.com/browse/ema/Zonisamide/9fa29fe42c687f7668ad4aba68f026e0?reference=41,2021.0,NS(=O)(=O)CC1=NOC2=CC=CC=C12
